Loading
A phase 1/2 trial of OH2 injection, with or without irinotecan or HX008 in advanced solid tumours, run by Binhui Biopharmaceutical Co., Ltd., now recruiting.
OH2 Oncolytic Viral Therapy in Solid Tumors is a phase 1/2 interventional study registered as NCT03866525 by Binhui Biopharmaceutical Co., Ltd., with 300 participants planned, started 2019-04-02 and due to reach its primary completion in 2025-08-30. Interventions recorded: OH2 injection, with or without irinotecan or HX008.
Shares Binhui Biopharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Binhui Biopharmaceutical and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.